Research programme: neurodegenerative disorders RNA interference-based therapeutics - Alnylam Pharmaceuticals
Latest Information Update: 16 May 2014
At a glance
- Originator Sirna Therapeutics
- Class Nucleic acids
- Mechanism of Action RNA interference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurodegenerative disorders; Spinocerebellar degeneration